Alternating hemiplegia of childhood- Sodium oxybate
Status: Open to Enrollment
Start Date: Jun 29 2009
End Date: OPEN
The purpose of this study is see if sodium oxybate can abort episodes of weakness/stiffness in children and young adults with alternating hemiplegia of childhood (AHC). Participants from ages 6 months to 25 years old who have on average at least 3 AHC episodes per week may be eligible. Primary caregivers of study participants will be required to submit online daily AHC episode logs indicating frequency and duration of episodes prior to and during use of study drug. A one-week stay at the University of Utah will be required for initial drug dosing and monitoring.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician. If you do not have a primary care physician, we can help you find a University of Utah doctor or clinic location to meet your health care needs.
Although the studies described on this Web site may have potential benefits as described, the University of Utah and its physicians and affiliated hospitals cannot and do not guarantee or promise that you will receive any benefits from participating in a study.
The information posted on this site is consistent with the research reviewed and approved by the University of Utah Institutional Review Board (IRB). However, the IRB has not reviewed all material posted on this site. Contact the IRB if you have questions regarding your rights as a research participant. Also contact the IRB if you have questions, complaint, or concerns which you do not feel you can discuss with the investigator. The University of Utah IRB may be reached by phone at (801) 581-3655 or by e-mail at firstname.lastname@example.org.